JP2018535648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535648A5 JP2018535648A5 JP2018513797A JP2018513797A JP2018535648A5 JP 2018535648 A5 JP2018535648 A5 JP 2018535648A5 JP 2018513797 A JP2018513797 A JP 2018513797A JP 2018513797 A JP2018513797 A JP 2018513797A JP 2018535648 A5 JP2018535648 A5 JP 2018535648A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 description 26
- 241000829111 Human polyomavirus 1 Species 0.000 description 17
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 7
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 4
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical group COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 4
- 229960004866 mycophenolate mofetil Drugs 0.000 description 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 4
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010055181 BK virus infection Diseases 0.000 description 2
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 2
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 2
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010023163 JC virus infection Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000004565 granule cell Anatomy 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004712 monophosphates Chemical group 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000006825 purine synthesis Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021153503A JP7284790B2 (ja) | 2015-09-16 | 2021-09-21 | ポリオーマウイルス中和抗体 |
| JP2023032616A JP7706489B2 (ja) | 2015-09-16 | 2023-03-03 | ポリオーマウイルス中和抗体 |
| JP2025110154A JP2025143348A (ja) | 2015-09-16 | 2025-06-30 | ポリオーマウイルス中和抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/089764 | 2015-09-16 | ||
| CN2015089764 | 2015-09-16 | ||
| PCT/IB2016/055339 WO2017046676A1 (en) | 2015-09-16 | 2016-09-08 | Polyomavirus neutralizing antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153503A Division JP7284790B2 (ja) | 2015-09-16 | 2021-09-21 | ポリオーマウイルス中和抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535648A JP2018535648A (ja) | 2018-12-06 |
| JP2018535648A5 true JP2018535648A5 (enExample) | 2019-10-17 |
| JP7053455B2 JP7053455B2 (ja) | 2022-04-12 |
Family
ID=56936456
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513797A Active JP7053455B2 (ja) | 2015-09-16 | 2016-09-08 | ポリオーマウイルス中和抗体 |
| JP2021153503A Active JP7284790B2 (ja) | 2015-09-16 | 2021-09-21 | ポリオーマウイルス中和抗体 |
| JP2023032616A Active JP7706489B2 (ja) | 2015-09-16 | 2023-03-03 | ポリオーマウイルス中和抗体 |
| JP2025110154A Pending JP2025143348A (ja) | 2015-09-16 | 2025-06-30 | ポリオーマウイルス中和抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153503A Active JP7284790B2 (ja) | 2015-09-16 | 2021-09-21 | ポリオーマウイルス中和抗体 |
| JP2023032616A Active JP7706489B2 (ja) | 2015-09-16 | 2023-03-03 | ポリオーマウイルス中和抗体 |
| JP2025110154A Pending JP2025143348A (ja) | 2015-09-16 | 2025-06-30 | ポリオーマウイルス中和抗体 |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US9862760B2 (enExample) |
| EP (2) | EP3350218B1 (enExample) |
| JP (4) | JP7053455B2 (enExample) |
| CN (2) | CN113929771B (enExample) |
| AR (1) | AR106043A1 (enExample) |
| AU (1) | AU2016322814B2 (enExample) |
| CA (1) | CA2995795A1 (enExample) |
| DK (1) | DK3350218T5 (enExample) |
| ES (1) | ES2973856T3 (enExample) |
| FI (1) | FI3350218T3 (enExample) |
| HR (1) | HRP20240413T1 (enExample) |
| HU (1) | HUE065935T2 (enExample) |
| IL (2) | IL296800A (enExample) |
| LT (1) | LT3350218T (enExample) |
| MX (2) | MX392098B (enExample) |
| PL (1) | PL3350218T3 (enExample) |
| PT (1) | PT3350218T (enExample) |
| RS (1) | RS65441B1 (enExample) |
| SI (1) | SI3350218T1 (enExample) |
| SM (1) | SMT202400124T1 (enExample) |
| TW (2) | TWI789744B (enExample) |
| UY (1) | UY36905A (enExample) |
| WO (1) | WO2017046676A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CN110546164B (zh) * | 2016-11-11 | 2023-10-20 | 锦湖Ht株式会社 | 特异性结合cd40的抗体及其用途 |
| CA3083363A1 (en) * | 2017-12-01 | 2019-06-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
| US10946238B1 (en) | 2018-07-23 | 2021-03-16 | Life Fitness, Llc | Exercise machines having adjustable elliptical striding motion |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| US12410238B2 (en) | 2019-06-19 | 2025-09-09 | Icahn School Of Medicine At Mount Sinai | Monoclonal antibodies against JC virus |
| WO2021236724A2 (en) * | 2020-05-20 | 2021-11-25 | Remd Biotherapeutics, Inc. | Human endothelin receptor a (etar) antagonist antibodies |
| MX2022015071A (es) * | 2020-06-09 | 2023-02-27 | Memo Therapeutics Ag | Moleculas de anticuerpo contra el virus bk. |
| BR112022025020A2 (pt) * | 2020-06-12 | 2023-02-14 | Vera Therapeutics Inc | Dosagem de anticorpos neutralizantes de poliomavírus |
| WO2022094238A2 (en) * | 2020-10-29 | 2022-05-05 | Flagship Pioneering Innovations V, Inc. | Chicken anemia virus (cav)-based vectors |
| WO2022152282A1 (zh) * | 2021-01-18 | 2022-07-21 | 江苏先声药业有限公司 | 抗人cd22的单克隆抗体及其用途 |
| KR20240006505A (ko) * | 2021-03-12 | 2024-01-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Bk 바이러스에 대한 중화 단클론성 항체 |
| WO2023175171A1 (en) | 2022-03-18 | 2023-09-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Bk polyomavirus antibodies and uses thereof |
| CA3254085A1 (en) * | 2022-05-18 | 2023-11-23 | The Brigham And Women's Hospital, Inc. | KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE |
| CN118725124B (zh) * | 2023-03-29 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 抗胃蛋白酶原ⅱ抗体、检测胃蛋白酶原ⅱ的试剂和试剂盒 |
| WO2025111317A1 (en) * | 2023-11-21 | 2025-05-30 | The Brigham And Women's Hospital, Inc. | Klrb1 binding agents and methods of use thereof |
| EP4659810A1 (en) | 2024-06-07 | 2025-12-10 | Université de Strasbourg | Bkv neutralizing antibodies |
| EP4659811A1 (en) * | 2024-06-07 | 2025-12-10 | Université de Strasbourg | Bk virus neutralizing antibodies |
| WO2025252935A1 (en) | 2024-06-07 | 2025-12-11 | Universite De Strasbourg | Bkv neutralizing antibodies |
| WO2025252939A1 (en) * | 2024-06-07 | 2025-12-11 | Universite De Strasbourg | Bk virus neutralizing antibodies |
| CN119320446B (zh) * | 2024-12-02 | 2026-01-20 | 上海云泽生物科技有限公司 | 一种抗bkv抗体及其应用 |
| CN120623324B (zh) * | 2025-08-13 | 2025-10-31 | 北京溯本源和生物科技有限公司 | 一种用于bk病毒vp1蛋白检测的单克隆抗体3c7及应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| EP2298345A3 (en) * | 2005-01-24 | 2012-03-21 | MedImmune Limited | Specific binding members for NGF |
| ME03057B (me) * | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Molekuli humanizovanih antitela specifični za il-31 |
| US8080244B2 (en) * | 2008-11-21 | 2011-12-20 | Los Alamos National Security, Llc | Anti-influenza M2e antibody |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| TW201233686A (en) | 2010-12-27 | 2012-08-16 | Japan Health Science Found | Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same |
| MX2013011363A (es) | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| ES2731757T3 (es) | 2012-03-20 | 2019-11-18 | Biogen Ma Inc | Anticuerpos neutralizantes de JCV |
| WO2013142300A2 (en) | 2012-03-20 | 2013-09-26 | Biogen Idec Ma Inc. | Jcv neutralizing antibodies |
| ITTO20120570A1 (it) * | 2012-06-27 | 2013-12-28 | Pomona Ricerca Srl | Anticorpo monoclonale diretto contro il virus jc |
| CN104936980B (zh) | 2012-12-31 | 2019-06-07 | 生物控股有限公司 | 用于治疗和预防多瘤病毒相关的疾病的重组人抗体 |
| WO2015095770A1 (en) | 2013-12-20 | 2015-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic jc polyomavirus compositions and methods of use |
| LT3099713T (lt) * | 2014-02-02 | 2020-07-10 | Medimmune Limited | Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno |
| WO2016105572A1 (en) | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| CA3083363A1 (en) | 2017-12-01 | 2019-06-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
| MX2022015071A (es) | 2020-06-09 | 2023-02-27 | Memo Therapeutics Ag | Moleculas de anticuerpo contra el virus bk. |
| BR112022025020A2 (pt) | 2020-06-12 | 2023-02-14 | Vera Therapeutics Inc | Dosagem de anticorpos neutralizantes de poliomavírus |
-
2016
- 2016-09-07 US US15/258,925 patent/US9862760B2/en active Active
- 2016-09-08 JP JP2018513797A patent/JP7053455B2/ja active Active
- 2016-09-08 LT LTEPPCT/IB2016/055339T patent/LT3350218T/lt unknown
- 2016-09-08 HR HRP20240413TT patent/HRP20240413T1/hr unknown
- 2016-09-08 HU HUE16766397A patent/HUE065935T2/hu unknown
- 2016-09-08 SM SM20240124T patent/SMT202400124T1/it unknown
- 2016-09-08 SI SI201631811T patent/SI3350218T1/sl unknown
- 2016-09-08 PT PT167663970T patent/PT3350218T/pt unknown
- 2016-09-08 FI FIEP16766397.0T patent/FI3350218T3/fi active
- 2016-09-08 IL IL296800A patent/IL296800A/en unknown
- 2016-09-08 CN CN202111169855.3A patent/CN113929771B/zh active Active
- 2016-09-08 EP EP16766397.0A patent/EP3350218B1/en active Active
- 2016-09-08 IL IL257541A patent/IL257541B2/en unknown
- 2016-09-08 RS RS20240355A patent/RS65441B1/sr unknown
- 2016-09-08 EP EP24158407.7A patent/EP4414385A3/en active Pending
- 2016-09-08 ES ES16766397T patent/ES2973856T3/es active Active
- 2016-09-08 AU AU2016322814A patent/AU2016322814B2/en active Active
- 2016-09-08 MX MX2018003282A patent/MX392098B/es unknown
- 2016-09-08 CN CN201680053963.5A patent/CN108026166B/zh active Active
- 2016-09-08 CA CA2995795A patent/CA2995795A1/en active Pending
- 2016-09-08 WO PCT/IB2016/055339 patent/WO2017046676A1/en not_active Ceased
- 2016-09-08 PL PL16766397.0T patent/PL3350218T3/pl unknown
- 2016-09-08 US US15/758,491 patent/US10450366B2/en active Active
- 2016-09-08 DK DK16766397.0T patent/DK3350218T5/da active
- 2016-09-13 TW TW110113971A patent/TWI789744B/zh active
- 2016-09-13 TW TW105129740A patent/TWI726911B/zh active
- 2016-09-16 AR ARP160102822A patent/AR106043A1/es unknown
- 2016-09-16 UY UY0001036905A patent/UY36905A/es not_active Application Discontinuation
-
2017
- 2017-12-01 US US15/829,115 patent/US10435460B2/en active Active
-
2018
- 2018-03-15 MX MX2022005253A patent/MX2022005253A/es unknown
- 2018-11-07 US US16/183,262 patent/US10654914B2/en active Active
-
2019
- 2019-10-18 US US16/657,855 patent/US11161894B2/en active Active
-
2021
- 2021-09-21 JP JP2021153503A patent/JP7284790B2/ja active Active
- 2021-10-15 US US17/502,910 patent/US11639378B2/en active Active
-
2023
- 2023-03-03 JP JP2023032616A patent/JP7706489B2/ja active Active
- 2023-03-17 US US18/186,064 patent/US12077571B2/en active Active
-
2024
- 2024-07-22 US US18/780,282 patent/US20250051423A1/en active Pending
-
2025
- 2025-06-30 JP JP2025110154A patent/JP2025143348A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535648A5 (enExample) | ||
| JP2022002524A5 (enExample) | ||
| JP7262440B2 (ja) | 抗ｃｄ４７抗体及びその使用 | |
| CN104105708B (zh) | PDGF受体β结合多肽 | |
| JP7293122B2 (ja) | 補体が媒介する疾患および障害を処置するための方法 | |
| TWI890481B (zh) | 雙特異性抗體 | |
| FI3350218T3 (fi) | Polyoomavirusta neutraloivia vasta-aineita | |
| US10858425B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| CN111620945A (zh) | 一种抗新型冠状病毒的单克隆抗体或其衍生体 | |
| JP2018508475A (ja) | 抗ｐｄ−ｌ１抗体 | |
| WO2013039954A1 (en) | Anti-gitr antibodies | |
| JP7230819B2 (ja) | 二重特異性抗体 | |
| JP2010501164A5 (enExample) | ||
| JP6914283B2 (ja) | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 | |
| JP2010527939A5 (enExample) | ||
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| CN106565840A (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| JP2024540148A5 (enExample) | ||
| WO2018184593A1 (zh) | 用于治疗乙肝感染及相关疾病的抗体 | |
| WO2022127793A1 (zh) | 呼吸道合胞病毒特异性结合分子 | |
| WO2021173844A1 (en) | C19 c38 bispecific antibodies | |
| EP4110818A1 (en) | C19 c38 bispecific antibodies | |
| WO2023236980A1 (zh) | 一种pvrig/tigit双特异性抗体药物组合物及其用途 | |
| TW202118790A (zh) | 雙特異性抗體 | |
| US20240109977A1 (en) | Anti-cd38 antibodies and their uses |